首页 | 本学科首页   官方微博 | 高级检索  
     


Signal Management in Pharmacovigilance: A Review of Activities and Case Studies
Affiliation:1. Américo Brasiliense State Hospital, Américo Brasiliense, Brazil;2. Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University, Araraquara, Brazil;3. Institute of Biomedicine - iBiMED, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal;1. Regional pharmacovigilance center, department of pharmacology, Pitié-Salpêtrière hospital, 47/83, boulevard de l’Hôpital, 75013 Paris, France;2. INSERM, CIC Pitié-Salpêtrière (CIC-1901), Sorbonne université, faculty of medicine, AP-HP, Pitié-Salpêtrière hospital, department of pharmacology and clinical investigation center, UNICO-GRECO Cardio-oncology program, 75013 Paris, France;1. Safety Sciences Research, Pfizer Inc, New York, NY, USA;2. Department of Medicine, NYU Langone Health, New York, NY, USA;3. Pharmaceutical Physician, Kent, United Kingdom
Abstract:PurposeAfter nearly 12 decades of pharmaceutical catastrophes and the associated groundbreaking regulatory innovations, pharmacovigilance has come down to us in the present day as 3 interlocking core disciplines: case management, signal management, and benefit–risk management. This review provides a state-of-the-art introduction to the great variety of sources of safety information, both dependent on and independent of the Individual Case Safety Report (ICSR), and explains how this content undergoes management-system processes with globally accepted definitions, standards, and structures that make possible the ongoing safe use of a pharmaceutical product throughout its lifecycle. This occurs in the context of: (1) new products coming to market with new risks for drug–drug interactions, and (2) new global threats to safe manufacturing and distribution.MethodsThis narrative review, reflective of the author's experience, uses a large-frame system of signal management developed by the Council for International Organizations of Medical Sciences VIII Working Group and modified by the author to include governance. A key feature of the review is the regular inclusion of relevant case studies to provide a backdrop of the unexpected, with resulting tragic outcomes, to the ever-evolving regulatory landscape.FindingsRegarding content, beyond the commonly appreciated sources of safety information that find their way into ICSRs are non–ICSR-based sources, including preclinical data, manufacturing data, findings from subject-matter experts who participate on data-monitoring committees, outside expert panels, advocacy groups, and independent investigator studies. Regarding process, it is important to recognize that governance is crucial in the effective conduct of signal management, in that subject-matter experts are essential to the scientific and medical aspects of decision making, and business and policy executives are essential in determining the final courses of action, as these decisions have implications for the company.ImplicationsSignal management is an integral part of pharmacovigilance practices that strive to obtain all of the information necessary for maintaining the safety profiles of a company's pharmaceutical and biological products, to support favorable benefit–risk balances, and to ensure safe use by health care providers and their patients.
Keywords:drug safety  pharmacovigilance  signal management
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号